Lumida
/ABUS
⌘K
Arbutus Biopharma Corp

Arbutus Biopharma Corp

ABUS
$4.56USD-3.80%-0.18 today

MARKET CAP

900.8M

P/E (TTM)

FWD P/E

DAY RANGE

$5 – $5

52W RANGE

$3
$5

AI Summary

Stalk
Buy NowMedium

ABUS remains in Stage 2 Advancing after clearing multi-month resistance with a Momentum Breakout and sustained Lockout Rally, confirming institutional demand. The medium-term bias is bullish, anchored by rising EMAs, but price is extended and overbought, elevating pullback risk. Under a Speculative strategy and the Lockout Rally override, continuation participation is justified now on hold above the breakout zone, with support at the 9/20 EMAs.

  • Phase IIa: 33% of patients achieved undetectable hepatitis B surface antigen
  • $131 M cash funds operations into Q4 2026
  • 2024 net cash burn of $63–67 M pressures $131 M cash balance
Full analysis →
Insider Trades8 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Feb 4, 2025SellABUSJ. Christopher NaftzgerGeneral Counsel and CCO11,333$3.28$900.8M-15.24%+48.05%$37.2K-11.61%10b5-1Buy Now
Feb 4, 2025SellABUSKaren SimsChief Medical Officer19,348$3.28$900.8M-15.24%+48.05%$63.5K-15.41%10b5-1Buy Now
Feb 4, 2025SellABUSDavid C HastingsChief Financial Officer22,183$3.28$900.8M-15.24%+48.05%$72.8K-12.19%10b5-1Buy Now
Feb 4, 2025SellABUSMichael J. McelhaughInterim President & CEO23,790$3.28$900.8M-15.24%+48.05%$78.1K-1.58%10b5-1Buy Now
Feb 2, 2024SellABUSKaren SimsChief Medical Officer4,358$2.31$900.8M-15.24%+48.05%$10.1K-0.82%10b5-1Buy Now
Feb 2, 2024SellABUSDavid C HastingsChief Financial Officer9,593$2.31$900.8M-15.24%+48.05%$22.2K-1.50%10b5-1Buy Now
Feb 2, 2024SellABUSMichael J. SofiaChief Scientific Officer9,982$2.31$900.8M-15.24%+48.05%$23.1K-0.52%10b5-1Buy Now
Feb 2, 2024SellABUSMichael J. McelhaughInterim President & CEO10,164$2.31$900.8M-15.24%+48.05%$23.5K-0.51%10b5-1Buy Now